—   to   provisions that would have limited monopoly protections for   pharmaceutical companies’   biologics. Those are advanced drugs used, for instance, in cancer treatments. The Obama administration  —   pressed by nearly every other nation, the generic drug industry and nonprofit health groups like Doctors Without Borders, all of which wanted quicker access to affordable lifesaving drugs   —   had agreed that drugmakers could keep production data secret for five to eight years, fewer than the 12 years in federal law. 